Plus Therapeutics, Inc. and SpectronRx have announced a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. This strategic partnership will enable SpectronRx to produce late-stage clinical and commercial supplies of Rhenium (186Re) Obisbemeda, reinforcing their mission of advancing nuclear medicine.
Company Information
Company
Plus Therapeutics
Location
4200 MARATHON BLVD.
Austin, Texas, United States
About
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs, including Austin and San Antonio, Texas.
AustinManufacturingBiotechnologyHealth CarePharmaceutical